NCT06317298View on ClinicalTrials.gov

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

NARecruitingINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

February 21, 2024

Primary Completion Date

August 1, 2025

Study Completion Date

December 1, 2025

Conditions

Renal Cell Carcinoma, Clear Cell, Somatic

Interventions

DRUG

Fruquintinib and Everolimus

Fruquintinib and Everolimus

Trial Locations (1)

Unknown

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors

lead

Peking University First Hospital

OTHER